



Universiteit  
Leiden  
The Netherlands

## Sclerostin : a key regulator of bone metabolism

Lierop, A.H.J.M. van

### Citation

Lierop, A. H. J. M. van. (2013, February 14). *Sclerostin : a key regulator of bone metabolism*. Retrieved from <https://hdl.handle.net/1887/20541>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/20541>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/20541> holds various files of this Leiden University dissertation.

**Author:** Lierop, Antoon van

**Title:** Sclerostin : a key regulator of bone metabolism

**Issue Date:** 2013-02-14

# Sclerostin

A Key Regulator of Bone Metabolism

A.H.J.M. van Lierop

Printing: IJskamp Drukkers

Layout: A van Lierop

Cover illustration: A van Lierop

The research described in this thesis was carried out within the FP7 program TALOS, financed by the European Union (HEALTH-F2-2008-20199, TALOS).

Publication of this thesis was financially supported by: Anna Fonds, J.E. Jurriaanse stichting, Nederlandse Vereniging voor Calcium en Bot, Amgen B.V., Eli Lilly Nederland B.V., Novartis Pharma B.V., Servier Nederland Farma B.V., Goodlife Healthcare B.V. and UCB Pharma B.V.

© A.H.J.M. van Lierop, the Netherlands 2012. All rights reserved. No part of this thesis may be reproduced or transmitted in any form of means, without permission of the author or, when appropriate, of the publishers of the publications.

# Sclerostin

A Key Regulator of Bone Metabolism

ter verkrijging van de graad van doctor aan de Universiteit van Leiden,  
op gezag van de Rector Magnificus prof. mr. P.F. van der Heijden,  
volgens besluit van het College voor Promoties,  
te verdedigen op donderdag 14 februari 2013 klokke 16.15  
door

A.H.J.M. van Lierop

Geboren te 's Gravenhage 1981



*Waar ik het tomeloos duister afzoek*

*Door tijd en donkere materie heen*

*Ontluikt, vanuit de verste uithoek*

*Een kleine ster, lichtjaren van z'n buur alleen*

*Voor miljarden jaren al bestaan*

*Slechts niet eerder door mens ontwaard*

*Nu schenk ik hem jouw naam*

*En zet hem daarmee op de kaart*

## **Promotiecommissie**

Promotor Prof. dr. S.E. Papapoulos

Co-promotor Dr. N.A.T. Hamdy

Overige leden Prof. dr. P.T.A.M. Lips, VUmc

Prof. dr. A.H.M. Taminiau, LUMC

Prof. dr. H. Pijl, LUMC

Prof. dr. A.R.M.M. Hermus, UMC Radboud

Prof. dr. C.W.G.M. Löwik, LUMC

Dr. N. Loveridge, University of Cambridge, UK

## **Contents**

---

<b>Preface</b>	<b>9</b>
<b>Chapter 1</b> The role of sclerostin in the pathophysiology of sclerosing bone dysplasias	15
<b>Chapter 2</b> Measurement of circulating sclerostin	35
<b>Chapter 3</b> Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover.	47
<b>Chapter 4</b> Van Buchem disease: Clinical, biochemical and densitometric features of patients and disease carriers.	69
<b>Chapter 5</b> Glucocorticoids are not always deleterious for bone.	89
<b>Chapter 6</b> Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment.	105
<b>Chapter 7</b> Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls.	117
<b>Chapter 8</b> Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus.	131
<b>Chapter 9</b> Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover.	147
<b>Summary and Conclusions</b>	165
<b>Samenvatting en Conclusies</b>	173
<b>List of publications</b>	181
<b>Curriculum Vitae</b>	185

